Europe Kidney Cancer Drugs Market by Product Type (Angiogenesis Inhibitors, Immunotherapies, Monoclonal Antibodies (mAbs), mTOR Inhibitors, and Generics), By Brand [Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib)] - Opportunity Analysis and Industry Forecast, 2020-2027
|
A03828
|
Pages: NA
|
Jul 2020 |
1881 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Europe Kidney Cancer Drugs Market
Request Now !Kidney cancer is a disease in which kidney cells become malignant and grow out of control, forming a tumor. The symptoms of renal cancer include blood in the urine, getting lumps or mass in sides or abdomen, weight loss, lethargy, and fever. The kidney cancer drug is normally given to patients who have reached stage four renal cell carcinoma.
Factors such as increasing incidences of kidney cancers due to reduced activity & sedentary lifestyle, growing geriatric population, and rise in cigarette smoking cases are the major factors that drive the market. However, high prices of branded drugs and side-effects associated with these drugs may hamper the growth of the kidney cancer drug market. Increase in R&D investments and introduction of novel molecules for drug delivery may boost the market opportunities in future.
The European kidney cancer drug market is segmented on the basis of product type, brand, and countries. Based on type, it is segmented into angiogenesis inhibitors, immunotherapies, monoclonal antibodies (mAbs), mTOR inhibitors, generics, and other products. On the basis of brand, the kidney cancer drug market is segmented into Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), and others. Geographically the market has been analyzed across Germany, UK, France, Italy, Spain, and rest of Europe.
The major players in the kidney cancer drug market are F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Onyx Pharmaceuticals Inc., Bayer AG, Active Biotech AB, Novartis AG, Amgen, Genentech, Inc., Cipla Limited, and Pfizer Inc.
Key Benefits
- The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate imminent investment pockets.
- Extensive analysis of the market has been conducted by following key product positioning and monitoring the top competitors within the market framework.
- It offers a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
- Key players have been profiled and their strategies thoroughly analyzed to understand the competitive outlook of the European market.
- Comprehensive analysis of all countries in Europe has been provided that determines prevailing opportunities.
Europe Kidney Cancer Drugs Market Key Segment:
By Product Type
- Angiogenesis Inhibitors
- Immunotherapies
- Monoclonal Antibodies (mAbs)
- mTOR Inhibitors
- Generics
- Other Products
By Brand
- Afinitor (Everolimus)
- Avastin (Bevacizumab)
- Inlyta (Axitinib)
- Nexavar (Sorafenib)
- Proleukin (Aldesleukin)
- Sutent (Sunitinib)
- Torisel (Temsirolimus)
- Votrient (Pazopanib)
- Others
By Country
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 EUROPE KIDNEY CANCER DRUGS MARKET, BY PRODUCT TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ANGIOGENESIS INHIBITORS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. IMMUNOTHERAPIES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. MONOCLONAL ANTIBODIES (MABS)
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. MTOR INHIBITORS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. GENERICS
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. OTHER PRODUCTS
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 EUROPE KIDNEY CANCER DRUGS MARKET, BY BRAND
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. AFINITOR (EVEROLIMUS)
5.2.1. Market size and forecast
5.3. AVASTIN (BEVACIZUMAB)
5.3.1. Market size and forecast
5.4. INLYTA (AXITINIB)
5.4.1. Market size and forecast
5.5. NEXAVAR (SORAFENIB)
5.5.1. Market size and forecast
5.6. PROLEUKIN (ALDESLEUKIN)
5.6.1. Market size and forecast
5.7. SUTENT (SUNITINIB)
5.7.1. Market size and forecast
5.8. TORISEL (TEMSIROLIMUS)
5.8.1. Market size and forecast
5.9. VOTRIENT (PAZOPANIB)
5.9.1. Market size and forecast
5.10. OTHERS
5.10.1. Market size and forecast
CHAPTER 6 EUROPE KIDNEY CANCER DRUGS MARKET, BY COUNTRY
6.1. OVERVIEW
6.2. KEY MARKET TRENDS
6.3. KEY GROWTH FACTORS AND OPPORTUNITIES
6.4. MARKET SIZE AND FORECAST
6.4.1. Germany market size and forecast
6.4.2. UK market size and forecast
6.4.3. France market size and forecast
6.4.4. Italy market size and forecast
6.4.5. Spain market size and forecast
6.4.6. Rest of Europe market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. F. HOFFMANN-LA ROCHE AG
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. GLAXOSMITHKLINE PLC
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. ONYX PHARMACEUTICALS INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. BAYER AG
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ACTIVE BIOTECH AB
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. NOVARTIS AG
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. AMGEN
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. GENENTECH, INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. CIPLA LIMITED
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. PFIZER INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
Europe Kidney Cancer Drugs Market- Opportunity Analysis and Industry Forecast, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $ 699/m
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Â T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.